Ponesimod, also known as ACT-128800, is a potent, and orally active selective S1P(1) agonist. Ponesimod activated S1P(1)-mediated signal transduction with high potency (EC(50) of 5.7 nM) and selectivity. Ponesimod prevented edema formation, inflammatory cell accumulation, and cytokine release in the skin of mice with delayed-type hypersensitivity. Ponesimod also prevented the increase in paw volume and joint inflammation in rats with adjuvant-induced arthritis. Ponesimod may represent a new therapeutic approach in lymphocyte-mediated autoimmune diseases.
Properties:
Boiling point: 658.0±65.0 °C(Predicted)
density: 1.30±0.1 g/cm3(Predicted)
pka: 13.38±0.20(Predicted)
S1P Receptor Inhibitors Related Products:
Fingolimod hydrochloride; JTE-013; Ozanimod